1-4 of 4
Massimo Mangiola
Close
Sort by
Journal Articles

Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis

Arnon P. Kater, Frank Dicker, Massimo Mangiola, Kate Welsh, Richard Houghten, John Ostresh, Adel Nefzi, John C. Reed, Clemencia Pinilla, Thomas J. Kipps
Journal: Blood
Blood (2005) 106 (5): 1742–1748.
https://doi.org/10.1182/blood-2005-02-0695
Published: 2005
Journal Articles

Anti-CD20 Antibody Rituximab and Anti-CD23 Antibody IDEC-152 Induce Apoptosis of Malignant B-Cells in Combination with Chemical Antagonists of XIAP.

Massimo Mangiola, Ph.D, Kate Welsh, Ph.D, Shinichi Kitada, MD, Ph.D., Irene M. Pedersen, Ph.D., Nuzhat Pathan, Ph.D., Clementia Pinilla, Ph.D., Thomas J. Kipps, MD, Ph. D, John C. Reed, MD, Ph.D
Journal: Blood
Blood (2004) 104 (11): 1401.
https://doi.org/10.1182/blood.V104.11.1401.1401
Published: 2004
Journal Articles

Inhibition of XIAP Renders Newly CD40-Activated Chronic Lymphocytic Leukemia Cells Sensitive to Fas (CD95) Mediated Apoptosis.

Arnon P. Kater, MD, Frank Dicker, PhD, Massimo Mangiola, PhD, Kate Welsh, John Ostresh, PhD, Richard Houghten, PhD, John C. Reed, MD, PhD, Thomas J. Kipps, MD, PhD, Clemencia Pinilla, PhD
Journal: Blood
Blood (2004) 104 (11): 3474.
https://doi.org/10.1182/blood.V104.11.3474.3474
Published: 2004
Journal Articles

Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemia

Simona Zupo, Giovanna Cutrona, Massimo Mangiola, Manlio Ferrarini
Journal: Blood
Blood (2002) 99 (6): 2277–2278.
https://doi.org/10.1182/blood-2001-11-0126
Published: 2002